Silgan Holdings Inc. (NYSE:SLGN) Q3 2023 Earnings Call Transcript

George Staphos: Yeah. No worries. Just to the extent that you have any commentary from your customers on anti-obesity drugs and the effect it’s having on human food and beverage. What are you hearing? What should we consider what you would not worry about? Any thoughts there would be great. Thanks and good luck in a quarter.

Adam Greenlee: Sure. Thank you. We’ve had several discussions with our customers. And I think for the most part, the non-pet food segment of our business for the earlier conversation. I think the discussion has largely been around what we do as our products provide nutrition to consumers and a tremendous value. And it’s a safe means of getting low-cost, high-value nutrition products to consumers. And so we do think that the consumers of our products likely won’t be candidates for this kind of weight loss application. And we also think that even though some may be that this is high nutrition product that we support. So snacks were not — are not a big part of what we do. We’ve got some of our beverage products that probably are closer, but we just don’t think according to our customers, if there’s any material impact for the foreseeable future from the advent of the GLP type applications.

George Staphos: Thank you, Adam.

Adam Greenlee: Sure.

Operator: And it appears there are no further telephone questions. I’d like to turn the conference back over to our presenters, for any additional or closing comments.

Adam Greenlee: Great. Thank you, Anna, and I appreciate everyone’s time today and interest in the company. Look forward to reviewing our year-end and our 2024 outlook in January.

Operator: And once again, that does conclude today’s conference. We thank you all for your participation. You may now disconnect.